Beside the previously mentioned success of targeting dysregulated metabolism of αKG in patients carrying IDH1 and IDH2 mutations, potential metabolic targets have been identified in AML subgroups with other molecular signatures. The gene discussed is IDH2; the disease is acute myeloid leukemia.